CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Naloxone +1 moredrug
Likely dose
Naloxone 4 mg intranasal, dose frequency not specifiedAI-extracted
Key inclusion· 4
  • ✓BMI ≥30 (obese)
  • ✓Self-reported binge eating meeting DSM-5 criteria in last 4 weeks
  • ✓If sexually active with men, must agree to contraception through final study visit
  • ✓Able to provide informed consent and comply with study requirements
Key exclusion· 10
  • ✕Pregnant or breastfeeding
  • ✕Severe hypotension (<90/60 mmHg)
  • ✕Current or recent use of vasoconstrictor or vasodilator medications
  • ✕Current or history of diabetes

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02805972
NCT02805972Phase 2Completed
CompareCT.gov

Biology and Experience of Eating in Women With Obesity

University of California, San Francisco·interventional·Posted Jun 20, 2016·Updated Nov 3, 2021

In Brief

A Phase 2 clinical trial evaluating Naloxone and Placebo for Obesity. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of this study is to understand how the opioid system is involved in eating behavior.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 20, 2016
Enrollment StartMay 20, 2017
Primary CompletionJul 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.0 years ago

Interventions

Naloxonedrug

4 mg / 0.1 ml

Placebodrug

0.1 ml